SNDX•benzinga•
Syndax's Revumenib Shows 67% CR, 88% ORR, And 100% MRD Negativity Among Responders In Combo With Venetoclax/Azacitidine For Older, Newly Diagnosed mNPM1 And KMT2Ar AML Patients; Phase 3 EVOLVE-2 Trial Now Enrolling; Published In The 'Journal Of Clinical
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga